Drug Profile
ImmuDyn
Latest Information Update: 09 Mar 2006
Price :
$50
*
At a glance
- Originator Able Laboratories
- Class Antivirals
- Mechanism of Action
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Idiopathic thrombocytopenic purpura
Most Recent Events
- 09 Mar 2006 Discontinued for HIV-associated Idiopathic thrombocytopenic purpura in USA, India (SC)
- 08 Feb 2001 No-Development-Reported for Idiopathic thrombocytopenic purpura in India (SC)
- 08 Feb 2001 No-Development-Reported for Idiopathic thrombocytopenic purpura in USA (SC)